skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Development of more efficacious Tc-99m organ imaging agents for use in nuclear medicine by analytical characterization of radiopharmaceutical mixtures. Progress report, May 1, 1980-April 30, 1981. [/sup 99m/Tc(NaBH/sub 4/)HEDP]

Technical Report ·
DOI:https://doi.org/10.2172/6723475· OSTI ID:6723475

High performance liquid chromatography (HPLC) was used to efficiently separate and detect the individual components in a radiopharmaceutical mixture. A procedure for separating Tc(NaBH/sub 4/)HEDP radiopharmaceutical analogues by anion exchange HPLC with uv-visible and ..gamma.. detection was developed. Such preparations consist of as many as 7 Tc-containing components, the relative quantities of which are highly dependent on the conditions during preparation and subsequent handling. The in vivo distributions of 3 of the isolated Tc-HEDP species were evaluated as skeletal imaging agents in normal rats. The chromatographically separated Tc-HEDP components exhibit distinctly different biodistributions which are related to the chromatographic characteristics of the individual components. These same Tc-HEDP components were evaluated for uptake in myocardial infarcts using the isoproterenol-induced necrosis model in the rat. The relative uptake of the various components in the infarcted heart parallels the skeletal uptake. An optically transparent thin layer electrochemical flow cell was developed and characterized. This cell enables optical and electrochemical measurements to be made simultaneously on individual Tc-HEDP complexes as they elute from the HPLC. These results demonstrate the potential presence of numerous technetium complexes in radiopharmaceuticals and the efficacy of HPLC as a mode of separation and detection of these complexes. One particular component in the Tc(NaBH/sub 4/)HEDP radiopharmaceutical analogue is more effective than the others for both skeletal and myocardial infarct uptake. This is strongly suggestive that a more efficacious radiopharmaceutical would result from the administration of this single component.

Research Organization:
Cincinnati Univ., OH (USA)
Sponsoring Organization:
USDOE Office of Environment, Safety and Health (EH)
DOE Contract Number:
AC02-80EV10380
OSTI ID:
6723475
Report Number(s):
DOE/EV/10380-1; TRN: 81-002627
Country of Publication:
United States
Language:
English